Sigma-Aldrich & Roche Enter Exclusive Distribution Agreement
News Mar 19, 2015
Sigma-Aldrich Corporation has signed an exclusive global distribution agreement with Roche.The agreement pairs Roche's high-quality Biochemical Reagents product portfolio with the industry-leading eCommerce and supply chain capabilities of Sigma-Aldrich.
Under the agreement, Sigma-Aldrich will employ its sales, marketing and eCommerce expertise, and leverage the strength of its relationships with the scientific community, to present and distribute the Roche Biochemical Reagents product portfolio, which includes kits and enzymes for cellular analysis, proteomics and conventional PCR applications.
"Sigma-Aldrich is excited to offer the global scientific community access to Roche's leading portfolio of scientific tools and reagents. The addition of these life science tools supports our strategy to augment our portfolio with products that accelerate customer scientific research programs," said Eric Green, Executive Vice President and President, Sigma-Aldrich Research. "We look forward to working with Roche in this relationship."
"This agreement allows us to provide more customers with access to high-quality Roche Biochemical Reagent products through Sigma-Aldrich's expanded eCommerce and distribution networks," said Paul Brown, Head of Roche Molecular Diagnostics. "In addition, this will provide us the flexibility to devote more resources to our primary focus areas."
Transition of the Roche portfolio to Sigma-Aldrich is expected to take place in 2015. In the interim, these products will continue to be available through existing Roche channels.
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019